Yamashita Yugo, Shiomi Hiroki, Morimoto Takeshi, Yaku Hidenori, Kaji Shuichiro, Furukawa Yutaka, Nakagawa Yoshihisa, Ando Kenji, Kadota Kazushige, Abe Mitsuru, Akao Masaharu, Nagao Kazuya, Shizuta Satoshi, Ono Koh, Kimura Takeshi
Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
Heart Vessels. 2017 Dec;32(12):1448-1457. doi: 10.1007/s00380-017-1021-4. Epub 2017 Jul 11.
Recent randomized clinical trials demonstrated that transradial approach was a preferred approach for primary percutaneous coronary intervention (PCI) in ST-elevation acute myocardial infarction (STEMI). However, clinical outcomes of transradial approach in STEMI have not been adequately evaluated yet in the real-world practice, which includes hemodynamically unstable high-risk patients. We identified 3662 STEMI patients who had primary PCI within 24 h after symptom onset and were treated by transradial (N = 471) or transfemoral (N = 3191) approach in the CREDO-Kyoto AMI registry. In the current analysis, we compared clinical characteristics and long-term outcomes between the 2 groups of patients treated by transradial approach and transfemoral approach. The prevalence of hemodynamically compromised patients (Killip II-IV) was significantly less in the transradial group than in the transfemoral group (19 vs. 25%, P = 0.002). Cumulative 5-year incidences of death/MI/stroke, and major bleeding were not significantly different between the transradial and transfemoral groups (26.7 vs. 25.9%, log-rank P = 0.91, and 11.3 vs. 11.5%, log-rank P = 0.71, respectively). After adjustment for confounders, the risks of the transradial group relative to the transfemoral group were not significant for both death/MI/stroke [Hazard ratio (HR) 1.15, 95% confidence interval (CI) 0.83-1.59, P = 0.41] and major bleeding (HR 1.29, 95% CI 0.77-2.15, P = 0.34). In the subgroup of hemodynamically compromised patients, there were also no significant differences in the risks for death/MI/stroke and major bleeding between the 2 groups. Clinical outcomes of transradial approach were not different from those of transfemoral approach in primary PCI for STEMI in the real-world practice.
近期的随机临床试验表明,经桡动脉途径是ST段抬高型急性心肌梗死(STEMI)患者进行直接经皮冠状动脉介入治疗(PCI)的首选途径。然而,在包括血流动力学不稳定的高危患者在内的实际临床实践中,经桡动脉途径在STEMI患者中的临床疗效尚未得到充分评估。我们在CREDO-Kyoto急性心肌梗死注册研究中,纳入了3662例症状发作后24小时内接受直接PCI治疗的STEMI患者,这些患者分别采用经桡动脉途径(N = 471)或经股动脉途径(N = 3191)进行治疗。在本次分析中,我们比较了经桡动脉途径和经股动脉途径治疗的两组患者的临床特征和长期预后。血流动力学不稳定患者(Killip II-IV级)在经桡动脉组中的比例显著低于经股动脉组(19% 对25%,P = 0.002)。经桡动脉组和经股动脉组的5年累积死亡/心肌梗死/卒中发生率以及大出血发生率无显著差异(分别为26.7% 对25.9%,对数秩检验P = 0.91;11.3% 对11.5%,对数秩检验P = 0.71)。在对混杂因素进行校正后,经桡动脉组相对于经股动脉组在死亡/心肌梗死/卒中方面的风险[风险比(HR)1.15,95%置信区间(CI)0.83 - 1.59,P = 0.41]以及大出血方面的风险(HR 1.29,95% CI 0.77 - 2.15,P = 0.34)均无统计学意义。在血流动力学不稳定患者亚组中,两组在死亡/心肌梗死/卒中和大出血风险方面也无显著差异。在实际临床实践中,STEMI患者直接PCI的经桡动脉途径临床疗效与经股动脉途径并无差异。